Does Humana Cover Saxenda? Formulary Status, Prior Authorization, and Appeals

Saxenda contains liraglutide 3 mg and works as a daily injectable GLP-1 receptor agonist. Novo Nordisk manufactures it, and the FDA has approved it for chronic weight management in adults whose BMI reaches 30 or higher, or 27 or higher if they have a weight-related health condition. Adolescents age 12 and up may also use it if they meet certain weight and BMI thresholds. Although Saxenda and Victoza (liraglutide 1.8 mg, which treats type 2 diabetes) contain the same active ingredient, Saxenda uses a higher dose formulated specifically for weight management.

Whether Humana covers Saxenda depends on the plan type, not on a single company-wide answer. Humana commercial plans can cover it with prior authorization and step therapy, though many exclude it or place it on a high-cost specialty tier. Most Humana Medicare Advantage plans do not cover it at all, because federal law directs Part D plans to exclude drugs used for weight loss unless Congress or CMS changes that policy. Neither point can be confirmed for a specific member without checking that member's own plan documents, because formularies change by plan year and by employer group.

The single most reliable fact-check step for any Humana member is to log in to the member portal and search the current plan's formulary for "liraglutide" or "Saxenda," or call the number on the insurance card and ask for the clinical policy bulletin. Everything below describes how coverage decisions for this class of drug typically work across commercial and Medicare Advantage insurers, based on public regulatory rules and general prior-authorization patterns. It is not a substitute for confirming a specific plan's current terms, and no Humana-specific policy document was available to verify exact tier placement, exact step-therapy sequencing, or exact turnaround times for this article.

Does Humana's commercial formulary include Saxenda?

Saxenda, when covered on a Humana commercial formulary, typically sits on a non-preferred brand or specialty tier rather than a preferred tier. Formularies are reviewed and can change quarterly, and self-funded employer plans can choose to exclude anti-obesity medications entirely regardless of what Humana's standard commercial formulary lists. This means two members with "Humana" insurance cards can have completely different coverage for the same drug.

When a non-preferred or specialty tier applies, coinsurance in the 30% to 50% range after the deductible is common in the broader insurance market for this drug category, which at a list price near $1,300 to $1,400 per month could mean several hundred dollars per fill out of pocket. Exact cost-sharing figures should be confirmed against the member's summary of benefits, since they vary by plan.

Several medical societies, including the Endocrine Society, have published guidance calling for broader insurance coverage of FDA-approved anti-obesity medications as part of comprehensive obesity treatment. That guidance reflects a professional society's recommendation, not a coverage mandate, and commercial payers including Humana are not required to adopt it.

Why most Humana Medicare Advantage plans exclude Saxenda

This is a federal policy issue, not a Humana-specific one. Under the Social Security Act, Medicare Part D has historically excluded drugs used for weight loss from the covered drug list. That exclusion applies across virtually all Part D and Medicare Advantage prescription drug (MA-PD) plans, including Humana's, and it holds even when a prescriber documents an obesity-related comorbidity such as type 2 diabetes or obstructive sleep apnea.

The Inflation Reduction Act's Part D redesign capped annual out-of-pocket drug costs for Part D-covered drugs, a change CMS has described in its public materials on the law (cms.gov). That cap only helps with drugs Part D actually covers. Because Saxenda is excluded from Part D on nearly every Medicare Advantage plan, the out-of-pocket cap does not apply to it for most enrollees.

Some Medicare Advantage plans have piloted limited anti-obesity drug coverage through supplemental benefit programs in specific plan years and service areas. Whether Humana offers this on any specific plan changes year to year and cannot be assumed; it should be checked directly for the plan year in question.

Practical Medicare Advantage paths: ask the prescriber whether a GLP-1 receptor agonist approved for type 2 diabetes (and therefore Part D-eligible) is clinically appropriate, contact Novo Nordisk's patient assistance program to ask about income-based free-drug eligibility, or plan to pay cash while comparing pharmacy discount programs.

What prior authorization for Saxenda typically requires

Nearly all Humana plans that cover Saxenda require prior authorization. The general pattern for this drug class, consistent with FDA labeling criteria, includes:

• A documented BMI of 30 or greater, or 27 or greater with a qualifying comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• Evidence of a structured lifestyle intervention (diet, exercise, or a supervised weight-management program) attempted for a period before the request
• On many commercial plans, documented trial and inadequate response to, or intolerance of, at least one lower-cost anti-obesity medication (commonly generic phentermine) before Saxenda is approved
• Renewal after an initial approval period, usually tied to documentation of meaningful weight loss from baseline

These are typical utilization-management criteria for the anti-obesity drug class generally. The exact thresholds, required documentation, and renewal rules for a specific Humana plan should be requested directly as a clinical policy bulletin, since payers word and apply these criteria differently.

The evidence a prior-authorization letter typically cites

The pivotal trial supporting Saxenda's approval, the SCALE Obesity and Prediabetes trial, is described in the FDA-approved prescribing information and randomized adults meeting the approved BMI criteria to liraglutide 3 mg or placebo, both paired with lifestyle counseling. The FDA label reports a clinically meaningful weight-loss advantage for liraglutide over placebo at 56 weeks (FDA label, accessdata.fda.gov). A prior-authorization letter citing the FDA label's own clinical studies section, rather than a secondhand summary, gives a reviewing medical director a document they can verify directly.

Comparative efficacy claims about other GLP-1 drugs, including specific percentage weight-loss figures for semaglutide 2.4 mg (Wegovy) or tirzepatide (Zepbound) from their pivotal trials, should be checked against each drug's own current FDA label before being used in an appeal letter. Numbers copied from secondary sources without checking the label are a common source of PA and appeal denials on technical grounds.

Appealing a Humana denial

A first denial is not final. Humana is required to provide a written denial reason. Many denials cite missing documentation (an outdated BMI, no lifestyle-intervention record, missing step-therapy proof) rather than a judgment that the drug is medically inappropriate, and those can sometimes be resolved by resubmitting with the missing records rather than filing a formal appeal.

If a formal appeal is needed:

1. Internal appeal. Commercial members generally have 180 days from the denial date to file; Medicare Advantage members have 60 days. Include updated BMI documentation, comorbidity labs, a record of prior treatment trials, and citations to the FDA label's clinical studies section. Humana must respond within a defined window (commonly around 30 calendar days for standard commercial appeals, faster for expedited Medicare Advantage requests) but the exact deadline should be confirmed on the denial letter itself.
2. External review. If the internal appeal fails, commercial members can request an independent external review through their state insurance department, which is binding on the insurer. Medicare Advantage members instead escalate to the Medicare Independent Review Entity process.

Claims that a specific percentage of denials are reversed on appeal circulate in patient-advocacy materials, but no verifiable primary source for a precise reversal rate was available for this article, so no number is stated here. What is well established is that appeals supported by complete, current clinical documentation succeed more often than appeals that simply restate the original request.

Step therapy: what usually comes before Saxenda

Where a Humana plan applies step therapy for anti-obesity drugs, the typical sequence starts with a lower-cost oral option, most often generic phentermine, before an injectable GLP-1 receptor agonist is approved. Some plans add a second oral step, such as phentermine-topiramate or naltrexone-bupropion, before advancing further. Plans that flag a drug "PA" without an "ST" flag on the formulary tool are not applying step therapy for that drug; the presence or absence of that flag should be checked directly rather than assumed.

Cost-saving options if Saxenda is not covered

A manufacturer savings card has historically been available to commercially insured patients to reduce out-of-pocket cost per fill, with eligibility explicitly excluding anyone with Medicare, Medicaid, Tricare, or VA coverage. Terms, discount amount, and annual caps are set by the manufacturer and change without notice, so current terms should be confirmed on the manufacturer's own site before relying on a specific dollar figure.

Separately, Novo Nordisk has historically operated a patient assistance program offering free drug to patients meeting income and insurance-status criteria. Eligibility rules and income thresholds should be verified directly with the program, since they are subject to change.

Saxenda compared with other GLP-1 options on a Humana formulary

A formulary exception request is a separate process from a standard prior authorization and is used when a covered alternative is contraindicated or has already failed. It requires its own documentation letter from the prescriber.

Stopping Saxenda if coverage ends mid-treatment

Weight regain after stopping a GLP-1 receptor agonist is a well-documented pattern across this drug class in clinical trial extension data, though the exact magnitude reported for liraglutide specifically should be checked against the current FDA label or a verified primary trial report rather than a secondhand percentage, since a precise regain figure could not be confirmed from a verifiable primary source for this article. Patients who anticipate a coverage gap (job change, formulary update, transition to Medicare Advantage) should talk with their prescriber before the gap occurs about options such as a short bridge supply, enrolling in a manufacturer assistance program during the transition, or switching to a covered alternative with medical supervision.

What is established, what is plausible, and what is not established

Established: Saxenda is FDA-approved for chronic weight management under specific BMI and comorbidity criteria. Medicare Part D has a longstanding statutory basis for excluding anti-obesity drugs, which affects Medicare Advantage prescription drug coverage industry-wide, not just Humana. Manufacturer savings cards and patient assistance programs, where offered, exclude patients with government insurance.

Plausible but unproven for any individual Humana plan: the specific tier, exact coinsurance percentage, exact step-therapy sequence, and exact appeal turnaround time described in general industry patterns above. These are common patterns for the anti-obesity drug class among commercial payers, not confirmed Humana policy text.

Not established in this article: any specific percentage of Humana denials overturned on appeal, any specific current Humana clinical policy bulletin language, and any Medicare Advantage supplemental benefit pilot covering Saxenda for a given plan year. These require direct verification with Humana for the reader's specific plan and plan year.

Decision framework: what to do next based on your plan and denial status

Use this to figure out the fastest path, given that formulary details cannot be predicted from outside the plan.